Download PDF
Kardiologie up2date 2009; 5(2): 90-95
DOI: 10.1055/s-0029-1214639
Hotline – Herzrhythmusstörungen

© Georg Thieme Verlag KG Stuttgart · New York

Neue Medikamente zur Behandlung von Vorhofflimmern – gibt es eine Alternative zu Amiodaron?

Alexander  Bauer, Hugo  A.  Katus
Further Information

Publication History

Publication Date:
01 July 2009 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

Atrial fibrillation is the most common arrhythmia requiring treatment interventions with a high prevalence in elderly patients. In elderly asymptomatic patients rate control is the therapy of choice, whereas in symptomatic patients antiarrhythmic therapy or pulmonary vein isolation would be preferred. However, many currently used antiarrhythmic drugs have limited efficacy and cause irreversible organ toxicity. Amiodarone is the most potent antiarrhythmic agent for the treatment of atrial fibrillation. However, its use is limited by toxic effects on thyroid, lungs, liver, cornea, skin, and peripheral nerves. Thus compound development is more focused on congeners of Amiodarone. Dronedarone is a noniodinated benzofuran with similar electrophysiological effects compared to Amiodarone. Other compounds are under investigation. This review summarizes preclinical and clinical findings of these agents.

Literatur

  • 1 Laughlin J C, Kowey P R. Dronedarone: a new treatment for atrial fibrillation.  J Cardiovasc Electrophysiol. 2008;  19 1220-1226
    CrossrefPubMedSearch in Google Scholar
  • 2 Verma A. Atrial-fibrillation ablation should be considered first-line therapy for some patients.  Curr Opin Cardiol. 2008;  23 1-8
    CrossrefPubMedSearch in Google Scholar
  • 3 Singh B N. Amiodarone as paradigm for developing new drugs for atrial fibrillation.  J Cardiovasc Pharmacol. 2008;  52 300-305
    CrossrefPubMedSearch in Google Scholar
  • 4 Doggrell S A, Hancox J C. Dronedarone: an amiodarone analogue.  Expert Opin Investig Drugs. 2004;  13 415-426
    CrossrefPubMedSearch in Google Scholar
  • 5 Christ T, Wettwer E, Voigt N. et al . Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation.  Br J Pharmacol. 2008;  154 1619-1630
    CrossrefPubMedSearch in Google Scholar
  • 6 Schmitt J, Ehrlich J R, Hohnloser S H. New antiarrhythmic drugs for the treatment of atrial fibrillation.  Herz. 2008;  33 562-567
    CrossrefPubMedSearch in Google Scholar
  • 7 Gautier P, Serre M, Cosnier-Pucheu S. et al . In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.  J Cardiovasc Pharmacol. 2005;  45 125-135
    CrossrefPubMedSearch in Google Scholar
  • 8 Gautier P, Guillemare E, Marion A. et al . Electrophysiologic characterization of dronedarone in guinea pig ventricular cells.  J Cardiovasc Pharmacol. 2003;  41 191-202
    CrossrefPubMedSearch in Google Scholar
  • 9 Djandjighian L, Planchenault J, Finance O. et al . Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.  J Cardiovasc Pharmacol. 2000;  36 376-383
    CrossrefPubMedSearch in Google Scholar
  • 10 Lalevée N, Nargeot J, Barrére-Lemaire S. et al . Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes.  J Cardiovasc Electrophysiol. 2003;  14 885-890
    CrossrefPubMedSearch in Google Scholar
  • 11 Touboul P, Brugada J, Capucci A. et al . Dronedarone for prevention of atrial fibrillation: a dose-ranging study.  Eur Heart J. 2003;  24 1481-1487
    CrossrefPubMedSearch in Google Scholar
  • 12 Singh B N, Connolly S J, Crijns H J. et al . EURIDIS and ADONIS Investigators. N Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.  Engl J Med. 2007;  357 987-999
    CrossrefPubMedSearch in Google Scholar
  • 13 Hohnloser S H, Crijns H J, van Eickels M. et al . ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation.  N Engl J Med. 2009;  360 668-678
    CrossrefPubMedSearch in Google Scholar
  • 14 Davy J M, Herold M, Hoglund C. et al . ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study.  Am Heart J. 2008;  156 527-0
    PubMedSearch in Google Scholar
  • 15 Kober L, Torp-Pedersen C, McMurray J J. et al . Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure.  N Engl J Med. 2008;  358 2678-2687
    CrossrefPubMedSearch in Google Scholar
  • 16 Tschuppert Y, Buclin T, Rothuizen L E. et al . Effect of dronedarone on renal function in healthy subjects.  Br J Clin Pharmacol. 2007;  64 785-791
    PubMedSearch in Google Scholar
  • 17 Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.  Europace. 2008;  10 647-665
    CrossrefPubMedSearch in Google Scholar
  • 18 Kowey P R, Aliot E M, Capucci A. et al . Placebo-controlled double-blind dose ranging study of the efficacy and safety of SSR149744C in patients with recentatrial fibrillation/flutter.  Heart Rhythm. 2007;  4 72 (abstract)
    PubMedSearch in Google Scholar
  • 19 Arya A, Silberbauer J, Sulke N, Camm A J. A phase 2 pilot study of the efficacy of AT-2042 in subjects with paroxysmal atrial fibrillation and implanted pacemakers.  Heart Rhythm. 2006;  3 164
    PubMedSearch in Google Scholar

Prof. Dr. med Alexander Bauer

Abteilung Kardiologie, Angiologie und Pneumologie
Universitätsklinikum Heidelberg

Im Neuenheimer Feld 410
69120 Heidelberg

Email: Alexander.Bauer@med.uni-heidelberg.de